WO2022077276A1 - Application d'une combinaison de nicotinamide mononucléotide et de lactobacillus fermentum dans la préparation d'une formulation pour soulager le photovieillissement de la peau - Google Patents
Application d'une combinaison de nicotinamide mononucléotide et de lactobacillus fermentum dans la préparation d'une formulation pour soulager le photovieillissement de la peau Download PDFInfo
- Publication number
- WO2022077276A1 WO2022077276A1 PCT/CN2020/120924 CN2020120924W WO2022077276A1 WO 2022077276 A1 WO2022077276 A1 WO 2022077276A1 CN 2020120924 W CN2020120924 W CN 2020120924W WO 2022077276 A1 WO2022077276 A1 WO 2022077276A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- preparation
- fermentum
- lactobacillus fermentum
- skin photoaging
- Prior art date
Links
- 241000186840 Lactobacillus fermentum Species 0.000 title claims abstract description 69
- 238000002360 preparation method Methods 0.000 title claims abstract description 42
- 229940012969 lactobacillus fermentum Drugs 0.000 title claims abstract description 41
- 206010051246 Photodermatosis Diseases 0.000 title claims abstract description 39
- 230000008845 photoaging Effects 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims abstract description 7
- DAYLJWODMCOQEW-TURQNECASA-O NMN(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(O)=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-O 0.000 title claims abstract 17
- 238000009472 formulation Methods 0.000 title claims abstract 4
- 230000019491 signal transduction Effects 0.000 claims abstract description 18
- 230000036542 oxidative stress Effects 0.000 claims abstract description 16
- 230000006378 damage Effects 0.000 claims abstract description 12
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 claims abstract 3
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 claims abstract 3
- 210000004027 cell Anatomy 0.000 claims description 15
- 230000005855 radiation Effects 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 9
- 230000009759 skin aging Effects 0.000 claims description 9
- 230000036541 health Effects 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- 230000006749 inflammatory damage Effects 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 239000007788 liquid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000004321 preservation Methods 0.000 claims description 4
- 235000013373 food additive Nutrition 0.000 claims description 3
- 239000002778 food additive Substances 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 235000013361 beverage Nutrition 0.000 claims description 2
- 210000002421 cell wall Anatomy 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 230000001086 cytosolic effect Effects 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims description 2
- 150000004676 glycans Chemical class 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006166 lysate Substances 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 230000003020 moisturizing effect Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims 1
- 239000003708 ampul Substances 0.000 claims 1
- 239000003292 glue Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 238000004659 sterilization and disinfection Methods 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 79
- 210000004185 liver Anatomy 0.000 abstract description 37
- 210000002966 serum Anatomy 0.000 abstract description 20
- 230000002757 inflammatory effect Effects 0.000 abstract description 17
- 108010057466 NF-kappa B Proteins 0.000 abstract description 16
- 102000003945 NF-kappa B Human genes 0.000 abstract description 16
- 230000003078 antioxidant effect Effects 0.000 abstract description 10
- 239000003963 antioxidant agent Substances 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 8
- 230000037380 skin damage Effects 0.000 abstract description 8
- 230000004913 activation Effects 0.000 abstract description 7
- 238000011161 development Methods 0.000 abstract description 7
- 230000004792 oxidative damage Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- DAYLJWODMCOQEW-TURQNECASA-N NMN zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)([O-])=O)O2)O)=C1 DAYLJWODMCOQEW-TURQNECASA-N 0.000 description 62
- 241000699670 Mus sp. Species 0.000 description 55
- 230000014509 gene expression Effects 0.000 description 35
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 description 28
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 20
- 102000016938 Catalase Human genes 0.000 description 17
- 108010053835 Catalase Proteins 0.000 description 17
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 16
- 230000001965 increasing effect Effects 0.000 description 16
- 108090001005 Interleukin-6 Proteins 0.000 description 15
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 15
- 102000004889 Interleukin-6 Human genes 0.000 description 14
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 13
- 241000699666 Mus <mouse, genus> Species 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 13
- 210000001519 tissue Anatomy 0.000 description 13
- 102000003814 Interleukin-10 Human genes 0.000 description 12
- 108090000174 Interleukin-10 Proteins 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 102000008186 Collagen Human genes 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 10
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 10
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 10
- 229920001436 collagen Polymers 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 9
- 102100039337 NF-kappa-B inhibitor alpha Human genes 0.000 description 9
- 230000003247 decreasing effect Effects 0.000 description 9
- 101001123331 Homo sapiens Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Proteins 0.000 description 8
- 102100028960 Peroxisome proliferator-activated receptor gamma coactivator 1-alpha Human genes 0.000 description 8
- 210000004207 dermis Anatomy 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 210000005228 liver tissue Anatomy 0.000 description 8
- 102100024395 DCC-interacting protein 13-alpha Human genes 0.000 description 7
- 108010009306 Forkhead Box Protein O1 Proteins 0.000 description 7
- 102100035427 Forkhead box protein O1 Human genes 0.000 description 7
- 101001053277 Homo sapiens DCC-interacting protein 13-alpha Proteins 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000007254 oxidation reaction Methods 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 102000004127 Cytokines Human genes 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 description 6
- 108010012715 Superoxide dismutase Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 210000003630 histaminocyte Anatomy 0.000 description 6
- 210000004969 inflammatory cell Anatomy 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000028709 inflammatory response Effects 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 108010005094 Advanced Glycation End Products Proteins 0.000 description 5
- 230000032683 aging Effects 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 4
- 102000005747 Transcription Factor RelA Human genes 0.000 description 4
- 108010031154 Transcription Factor RelA Proteins 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000011506 response to oxidative stress Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010004146 Basal cell carcinoma Diseases 0.000 description 3
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 3
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000037356 lipid metabolism Effects 0.000 description 3
- -1 oral ampoules Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 239000003642 reactive oxygen metabolite Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 102000004315 Forkhead Transcription Factors Human genes 0.000 description 2
- 108090000852 Forkhead Transcription Factors Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108010041191 Sirtuin 1 Proteins 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- 208000028990 Skin injury Diseases 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004900 autophagic degradation Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037149 energy metabolism Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 210000005229 liver cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000006540 mitochondrial respiration Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229960003966 nicotinamide Drugs 0.000 description 2
- 235000005152 nicotinamide Nutrition 0.000 description 2
- 239000011570 nicotinamide Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 201000008261 skin carcinoma Diseases 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000003808 Adiponectin Receptors Human genes 0.000 description 1
- 108090000179 Adiponectin Receptors Proteins 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 101001059929 Caenorhabditis elegans Forkhead box protein O Proteins 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 102100030013 Endoribonuclease Human genes 0.000 description 1
- 101710199605 Endoribonuclease Proteins 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 102000026633 IL6 Human genes 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 1
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 108010077850 Nuclear Localization Signals Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 108010003541 Platelet Activating Factor Proteins 0.000 description 1
- 206010063493 Premature ageing Diseases 0.000 description 1
- 208000032038 Premature aging Diseases 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 206010039796 Seborrhoeic keratosis Diseases 0.000 description 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
- 102100026715 Serine/threonine-protein kinase STK11 Human genes 0.000 description 1
- 101710181599 Serine/threonine-protein kinase STK11 Proteins 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102100032891 Superoxide dismutase [Mn], mitochondrial Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JQRLYSGCPHSLJI-UHFFFAOYSA-N [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 Chemical compound [Fe].N1C(C=C2N=C(C=C3NC(=C4)C=C3)C=C2)=CC=C1C=C1C=CC4=N1 JQRLYSGCPHSLJI-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000009621 actinic keratosis Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000003373 basosquamous carcinoma Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008809 cell oxidative stress Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000003081 coactivator Effects 0.000 description 1
- 208000030381 cutaneous melanoma Diseases 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000019439 energy homeostasis Effects 0.000 description 1
- 239000002375 environmental carcinogen Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000036252 glycation Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 208000000069 hyperpigmentation Diseases 0.000 description 1
- 230000003810 hyperpigmentation Effects 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940072205 lactobacillus plantarum Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- JTSLALYXYSRPGW-UHFFFAOYSA-N n-[5-(4-cyanophenyl)-1h-pyrrolo[2,3-b]pyridin-3-yl]pyridine-3-carboxamide Chemical compound C=1C=CN=CC=1C(=O)NC(C1=C2)=CNC1=NC=C2C1=CC=C(C#N)C=C1 JTSLALYXYSRPGW-UHFFFAOYSA-N 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000003614 peroxisome proliferator Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 230000007084 physiological dysfunction Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000004983 pleiotropic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000006041 probiotic Substances 0.000 description 1
- 235000018291 probiotics Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000029964 regulation of glucose metabolic process Effects 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 201000003385 seborrheic keratosis Diseases 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000003708 skin melanoma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 108010045815 superoxide dismutase 2 Proteins 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- the invention belongs to the field of biomedicine, and in particular relates to the application of nicotinamide mononucleotide and Lactobacillus fermentum in combination in preparing a preparation for relieving skin photoaging.
- the skin is one of the largest and most complex organs in the human body, accounting for about 15% of body weight, and it is also the first line of defense against various environmental aggressions.
- Skin aging is an important part of body aging, which is not only detrimental to beauty, but also closely related to the occurrence of many skin diseases such as seborrheic keratosis, solar keratosis, basal cell carcinoma, and squamous cell carcinoma.
- Photoaging refers to the premature aging of the skin caused by repeated light exposure, and its clinical manifestations, histopathological and biochemical changes are different from the natural aging of the skin.
- Photoaging leads to a decrease in the number of mature type I collagen and elastic fibers in the dermis of the skin, and its clinical features are mainly manifested as skin roughness, loss of elasticity, deepening and thickening of wrinkles, leather-like appearance, and hyperpigmentation in exposed areas such as the face, neck, and forearm and telangiectasia.
- NMSCs non-melanoma skin cancers
- BCCs basal cell carcinomas
- SCCs squamous cell carcinomas
- Skin anti-aging has become a research hotspot of many scholars and clinicians in today's society, and it is also one of the hot areas that many beauty seekers pay attention to. In view of this, it is particularly important to establish a feasible photoaging model for in-depth study of its occurrence and development mechanism and screening of anti-photoaging drugs. Studies have shown that the occurrence and development of UV radiation-mediated skin photoaging involves multiple pathways, including apoptosis, proliferation, autophagy, DNA repair, checkpoint signal transduction, cell transduction, and inflammation.
- UVA 315nm-400nm
- UVB 280nm-315nm
- UVC 200nm-280nm
- UVB 280-315nm
- UVB UVB radiation only accounts for 1-2% of the sun's ultraviolet rays, it is considered to be the main environmental carcinogen that causes skin cancer and is related to the occurrence and development of tumors.
- the animal model is the most widely used photoaging model at home and abroad, and UVB is often used for modeling, because the skin tissue changes caused by UVB are very similar to human photoaging skin.
- Nicotinamide ribonucleotide is synthesized from nicotinamide (Nic) and 5'-phosphate pyrophosphate by nicotinamide phosphotransferase (NAMPT) and is a key intermediate of NAD + .
- NAMPT nicotinamide phosphotransferase
- NMN has been shown to enhance NAD + biosynthesis and improve various pathologies in mouse disease models, such as myocardial and cerebral ischemia, neurodegenerative diseases such as Alzheimer's disease, and diabetes.
- NMN nicotinamide mononucleotide
- Lactobacillus fermentum is a gram-positive bacterium and is widely distributed in nature. They have important application value in important fields closely related to human life, such as industry, agriculture, animal husbandry, food and medicine.
- the health benefits of Lactobacillus fermentum include regulating the immune system, regulating the balance of intestinal flora, lowering serum cholesterol and reducing the risk of tumors.
- some Lactobacillus fermentum were found to have other important biological functions, such as anti-aging and antioxidant activities, attracting more and more researchers' attention.
- Some studies have found that oral administration of live bacteria of Lactococcus lactis subsp. cremoris H61 or heat-killed bacteria can improve the skin condition of Japanese women.
- the invention explores the relevant reagents for relieving skin photoaging, adopts UVB-induced skin damage mouse model, and then gives mice nicotinamide mononucleotide combined with L. fermentum bacterial suspension for gavage treatment, and finally through the oxidation of serum and skin index, inflammatory index, mRNA expression level and protein expression of related genes in skin and liver to evaluate the improvement effect of NMN combined with L. fermentum on UVB-induced skin damage in mice, so as to find new ways to prevent skin aging or develop NMN combined
- the new probiotics of Lactobacillus fermentum provide theoretical reference and available raw materials.
- the purpose of the present invention is to provide a new use of nicotinamide mononucleotide (NMN) combined with L. fermentum.
- NPN nicotinamide mononucleotide
- the first aspect of the present invention provides the application of nicotinamide mononucleotide in combination with Lactobacillus fermentum L. fermentum in the preparation of preparations for relieving skin aging.
- the application of nicotinamide mononucleotide in combination with Lactobacillus fermentum in the preparation of preparations for relieving skin photoaging is provided, and the preparation forms include medicines, health products and skin care products.
- Lactobacillus fermentum Lactobacillus fermentum form is different: when the preparation is a drug, health product or food additive, the Lactobacillus fermentum Lactobacilus fermentum is in the form of intermittently sterilized Lactobacillus fermentum cells or lysate; when the preparation is a skin care product When produced, Lactobacillus fermentum Lactobacilus fermentum is in the form of metabolites, cytoplasmic fragments, cell wall components or polysaccharide complexes of Lactobacillus fermentum.
- the intermittently sterilized Lactobacillus fermentum cells are in the form of freeze-dried powder
- the concentration ratio between the nicotinamide mononucleotide and the intermittently sterilized Lactobacillus fermentum cells is 1:1
- the nicotinamide mononucleotide The concentration was 30 mg/mL
- the concentration of Lactobacillus fermentum cells was 10 9 CFU/mL.
- the photoaging skin is skin aging caused by ultraviolet radiation
- the skin aging caused by ultraviolet radiation is skin photoaging induced by medium-wave ultraviolet radiation.
- the preparation for relieving skin photoaging is a preparation for alleviating oxidative stress damage induced by ultraviolet radiation and reducing inflammatory damage in the body.
- the preparation is an agent for activating the AMPK signaling pathway, thereby inhibiting the activation of the NF ⁇ B-p65 signaling pathway, and further reducing the damage of the body caused by oxidative stress and inflammatory responses.
- the active ingredients of the preparation for relieving skin photoaging in the present invention only include nicotinamide mononucleotide and Lactobacilus fermentum.
- the medicines for relieving skin photoaging are gels, ointments, emulsions, aerosols, injections, mixtures, oral ampoules, tablets or capsules;
- the health care products for relieving skin photoaging are capsules, tablets, oral Liquid or solid beverages;
- skin care products for relieving skin photoaging are liquids, creams, moisturizing powders or masks.
- the present invention conducts experiments through the UVB-induced mouse skin injury model, and it is verified through experiments that NMN combined with L. fermentum activates the AMPK signaling pathway, thereby inhibiting the activation of the NF- ⁇ B signaling pathway and reducing the damage of inflammatory mediators to mice.
- activated AMPK can reduce the oxidative damage of the skin and improve the overall antioxidant capacity of the body by regulating the levels of related oxidative stress indicators in the serum, liver and skin of mice. Therefore, the present invention has certain reference significance for the prevention and treatment of skin damage caused by UVB, and provides a theoretical basis and an available strain source for the development of the preparation of NMN combined with Lactobacillus fermentum.
- Figure 1 is a comparison chart of the liver organ indexes of mice in different experimental groups. The data are presented as mean ⁇ standard deviation ( ⁇ SD), where * means p ⁇ 0.05, ** means p ⁇ 0.01, and *** means p ⁇ 0.001;
- Figure 2 is the observation of the pathological morphology of the liver in different experimental groups
- Figure 3 is the observation of skin pathological morphology in different experimental groups, (A) skin H&E staining; (B) skin Masson staining; (C) skin TB staining;
- Figure 3 shows the mRNA expression levels of SOD1, SOD2, CAT and GSH in skin and liver tissues, data are presented as mean ⁇ standard deviation ( ⁇ SD), where * means p ⁇ 0.05, ** means p ⁇ 0.01, *** means p ⁇ 0.001;
- Figure 4 shows the mRNA expression levels of AMPK, NF- ⁇ Bp65, I ⁇ B- ⁇ , SOD1 and CAT in skin and liver tissues, data are presented as mean ⁇ standard deviation
- * means p ⁇ 0.05, ** means p ⁇ 0.01, *** means p ⁇ 0.001;
- Figure 5 shows the mRNA expression levels of PGC-1 ⁇ , APPL1, mTOR, FOXO1, TNF- ⁇ , IL-6, IL-10 and GSH in skin and liver tissues, data are presented as mean ⁇ standard deviation
- * means p ⁇ 0.05, ** means p ⁇ 0.01, and *** means p ⁇ 0.001.
- NMN was provided by Yinfu Pharmaceutical Technology Co., Ltd. (Shanghai, China). The purity of NMN was determined by high performance liquid chromatography, and the purity was >98.5%.
- Lactobacillus fermentum was isolated and purified from natural fermented yak yogurt in Xinjiang.
- mice Forty 7-week-old female Kunming mice were purchased from the Experimental Animal Center of Chongqing Medical University [Chongqing, China, SCXK(YU) 2018-0003]. Mice were housed under constant temperature and humidity conditions (temperature 25 ⁇ 2°C, relative humidity 50 ⁇ 5%), 12h light/dark cycle. Mice were allowed free access to standard rat chow and drinking water.
- mice Forty mice were randomly divided into 4 groups with 10 mice in each group, namely normal group, model group, VC group, and NMN+L.fermentum group (NMN+L).
- the UVB modeling method is as follows: the whole experimental period is 4 weeks. From the 3rd week, the skin damage model of the mice in the other groups except the normal group is established by using ultraviolet radiation equipment, irradiating for 2h every day. Before UV irradiation, an electric shaver was used to shave about 2 cm 2 of hair on the back of the mice.
- mice were administered free food and water; the mice in the VC group were given VC solution by gavage at a dose of 300 mg/kg.bw every day; Mice were orally gavaged with NMN, and at the same time, 1.0 ⁇ 10 9 CFU/mL bacterial suspension was orally administered to mice every day. All experiments were approved by the Chongqing Functional Food Collaborative Innovation Center.
- Example 2 NMN+L.fermentum can improve liver organ index and tissue pathological morphology in mice after UV irradiation
- mice After four weeks of culture, the mice were sacrificed by devertebral method, the mice were dissected to remove the liver and the hairless skin of the back of the mice, and the organ index of the liver was calculated. The results are shown in Figure 1.
- liver and skin tissues were cut and fixed in 4% paraformaldehyde solution, and the remaining liver and skin tissues were stored in a -80°C refrigerator for later use.
- the liver was stained with H&E and the skin was stained with H&E, Masson's trichrome and toluidine blue. Finally, an upright microscope was used to observe the pathological morphology of the tissue, and the results are shown in Figure 2 and Figure 3:
- the mouse organ index can directly reflect the structural changes and functions of organs, and is of great significance for evaluating the functional properties of test samples.
- the liver organ index of the mice in the model group was significantly reduced, indicating that UV irradiation not only directly accelerates skin aging, but also indirectly causes liver aging. oxidative stress or induced inflammatory response.
- the liver organ index of the mice was significantly improved, indicating that NMN combined with L. fermentum can maintain the normal weight of the mouse liver and delay the aging of the liver.
- the liver structure of the mice in the normal group was complete, and the hepatocytes were neatly arranged around the central vein in a satellite emission pattern.
- the nuclei were large and round, and there was no infiltration of inflammatory cells.
- the liver cells in the VC group were relatively disordered, with partial necrosis and infiltration of inflammatory cells around the central vein, and the overall structural integrity of the liver was worse than that in the normal group.
- the phenomenon of cell infiltration; compared with the model group and the VC group, the shape of the liver cells in the NMN+L group was significantly more complete, and there was almost no cell necrosis and inflammatory cell infiltration, and the overall structure of the liver was similar to the normal group.
- H&E staining is mainly used to observe the overall structure of the skin
- Masson staining is mainly used to observe collagen fibers in the skin
- TB staining is mainly used to observe mast cells in the skin.
- the thickness of the skin dermis of the mice in the NMN+L group was significantly increased, and the collagen fiber bundles were not broken, shrunken and glued, and the overall structure was similar to that of the normal group.
- Collagen fibers were blue-purple after Masson staining. It can be seen from Figure 3(B) that the normal group has a large number of collagen fibers, and the distribution is uniform and orderly. The number of collagen fibers in the model group was significantly less than that in the normal group, and the phenomenon of breakage and shrinkage appeared. The number of collagen fibers in the dermis of the skin of the mice in the VC group was less than that in the normal group, but higher than that in the model group. Compared with the model group and the VC group, the number of collagen fibers in the dermis of the mice in the NMN+L group increased more, the arrangement was more orderly, and there was almost no shrinkage or breakage.
- the skin dermis of the UVB group mice became thinner, the number of collagen fibers decreased, the number of mast cells increased, and at the same time, the liver tissue also showed a certain degree of pathological changes, indicating that the UVB-induced skin damage model was successful.
- the pathological morphology of the skin was greatly improved, and the liver of the mice also remained in a normal shape without obvious damage.
- Example 3 NMN+L.fermentum can improve oxidative stress injury in UVB mice
- Oxidative stress is one of the important factors of UVB-induced skin aging. Under normal circumstances, the generation and scavenging of oxygen free radicals are in a state of balance. When stimulated by the outside world, the body will generate a large amount of oxygen free radicals due to local hypoxia, resulting in cell apoptosis or damage.
- Superoxide dismutase (SOD) is an enzyme containing metal cofactors, which can remove (disproportionate) the superoxide anion produced by the body and play an important role in the process of anti-aging and oxidation. With the progress of lipid peroxidation in the body, a large amount of SOD can be consumed, which in turn induces serious damage to the body.
- Catalase is an enzyme scavenger, also known as catalase, which is a conjugated enzyme with iron porphyrin as a prosthetic group. It can promote the decomposition of H 2 O 2 into molecular oxygen and water, so as to protect cells from the poison of H 2 O 2 , and is one of the key enzymes in the biological defense system.
- MDA is the final product of lipid oxidation. It can affect mitochondrial respiratory chain complexes and key enzyme activities in mitochondria in vitro. Its production can also aggravate membrane damage. Therefore, the determination of malondialdehyde content can reflect lipid peroxidation in the body. degree, which indirectly reflects the degree of cell damage.
- Glutathione as an important antioxidant in the body, can scavenge free radicals in the human body; because GSH itself is susceptible to oxidation by certain substances, it can protect the sulfhydryl groups in many proteins and enzymes in the body It is not oxidized by harmful substances, so as to ensure the normal functioning of molecular physiological functions such as proteins and enzymes.
- Advanced glycation end products AGEs are the end products of non-enzymatic glycation reactions, and their production and accumulation in serum and tissues increase with age. The protein modification of AGEs in the human body is closely related to the occurrence of senile diseases, so it can be used as an important indicator to test the aging process.
- the skin When continuously exposed to UV light, the skin will produce a strong oxidative stress response, releasing a large amount of reactive oxygen species (ROS), and ROS as an upstream signal will further initiate the NF- ⁇ B-mediated inflammatory pathway, thereby making the skin appear dry , itching, erythema and edema and other inflammatory symptoms.
- ROS reactive oxygen species
- the nuclear transcription factor NF- ⁇ B and its inhibitory protein I ⁇ B are combined together and exist in the cell in a resting manner.
- I ⁇ B- ⁇ is a repressor protein of NF- ⁇ B, which can mask the nuclear localization signal of NF- ⁇ B, so that NF- ⁇ B exists in the cell in the form of an inactive complex. Studies have shown that almost all NF- ⁇ B inducers rapidly activate NF- ⁇ B due to the degradation of I ⁇ B- ⁇ , so the activation of NF- ⁇ B can be prevented by preventing the phosphorylation of I ⁇ B- ⁇ .
- TNF- ⁇ is a cytokine with a wide range of biological activities, which is mainly secreted by activated monocyte-macrophages and T cells, which can lead to the aggregation of inflammatory cells and stimulate the production of inflammatory cytokines by inflammatory cells, eventually leading to Inflammation.
- IL-6 is a pleiotropic pro-inflammatory cytokine with biological activity, and its role is similar to IL-1 ⁇ . It can also activate the NF- ⁇ B signaling pathway to a certain extent, thereby causing chronic inflammation in the skin.
- IL-6 can increase the permeability of the skin, allowing inflammatory factors to infiltrate the inflammatory site and initiate inflammation.
- IL-10 is an important negative regulatory cytokine, which has a blocking effect on multiple links in the development of immune inflammatory response, has a wide range of immunosuppressive activities, and can inhibit the production of activated monocytes-macrophages
- Other cytokines including IL1, IL6, granulocyte colony stimulating factor, TNF, platelet activating factor, etc. have strong immunosuppressive functions.
- T-SOD, CAT, MDA and AGEs in mouse serum were determined according to the instructions of conventional biochemical kits, and the levels of TNF- ⁇ , IL-6 and IL-10 in mouse serum were determined according to the instructions of ELISA kits. The results are shown in the table. 1 shown.
- T-SOD, CAT, Na + K + -ATP and NAD + in mouse serum were determined according to the instructions of conventional biochemical kits, and the levels of TNF- ⁇ and IL-10 in serum and skin tissue were determined according to the instructions of ELISA kits, respectively , and the results are shown in Table 2.
- NMN combined with L. fermentum can increase the enzyme activities of T-SOD and CAT in serum and skin tissue of mice, increase the mRNA expression of SOD and CAT in liver and skin, and reduce the content of AGEs and MDA in serum.
- NMN combined with L. fermentum can greatly increase the levels of T-SOD and CAT in serum, and the enzyme activity of T-SOD is even higher than that of the normal group.
- the above results indicate that NMN combined with Lactobacillus fermentum can resist the oxidative stress of the skin caused by UVB irradiation in mice by increasing the activity of antioxidant enzymes, and can also improve the overall antioxidant level of the body from the levels of serum and liver.
- NMN combined with L. fermentum can down-regulate the expression of pro-inflammatory cytokines TNF- ⁇ and IL-6 and up-regulate the expression of anti-inflammatory cytokine IL-10 from the serum level, skin tissue level and mRNA level, respectively, thereby reducing the The degree of inflammatory damage caused by these inflammatory mediators to skin-injured mice.
- Example 4 NMN+L.fermentum can activate AMPK signaling pathway
- AMP-activated protein kinase is a serine/threonine protein kinase, which is a heterotrimer formed by catalytic subunits ⁇ and ⁇ and regulatory subunit ⁇ . AMPK is mainly involved in the regulation of glucose, lipid and energy metabolism in the body. Studies have shown that AMPK activation can inhibit inflammation and oxidative stress.
- AMPK can also act on nuclear transcription factor NF- ⁇ B and other inflammatory factors to regulate inflammation through various pathways, becoming a potential therapeutic target for various metabolic diseases such as diabetes and obesity and various inflammatory diseases.
- NF- ⁇ B nuclear transcription factor
- AMPK can effectively regulate the expression, migration and adhesion of inflammatory cytokines, thereby affecting the inflammatory response.
- inhibition of AMPK activity can significantly enhance the expression of inflammatory factors such as TNF- ⁇ , IL-1 ⁇ , and IL-6, thereby aggravating inflammatory damage.
- high expression of AMPK promotes the activity of factors such as SIRT1, FOXO, and PGC1 ⁇ , which in turn inhibits NF- ⁇ B activity. After cellular aging, NF- ⁇ B signaling is enhanced due to decreased AMPK activity.
- Adiponectin receptor-binding protein belongs to the upstream gene of AMPK. It is a functional protein composed of 709 amino acids and located on chromosome 3. It can mediate a variety of cell signal transduction and play a role in a variety of cellular responses. It can regulate the inflammatory response of cells, anti-oxidation and arteriosclerosis.
- Target of rapamycin mTOR is a downstream molecule in the AMPK signaling pathway, which mainly controls cell growth by regulating protein translation, and is involved in regulating cell immunity and apoptosis.
- Activated AMPK can inhibit the activity of mTOR, inhibit the synthesis and translation of proteins, and then play a negative role in regulating tumor growth.
- Activation of the mTOR pathway is thought to be closely related to the pathogenesis of cutaneous melanoma.
- Forkhead transcription factor O1 (FOXO1) is a member of the forkhead box family, which is mainly involved in the regulation of various physiological and biochemical processes such as cellular oxidative stress, cycle arrest, autophagy, and metabolism.
- peroxisome proliferator gamma coactivator alpha can participate in mitochondrial biosynthesis by regulating adaptive heat production, glucose and lipid metabolism, and blood sugar balance, and improve mitochondrial respiration and oxidation. ability to regulate fatty acid oxidation.
- PGC-1 ⁇ can regulate the body's adaptive heat production, glucose and lipid metabolism and blood sugar balance, participate in mitochondrial biosynthesis, and improve mitochondrial respiration and oxidation capacity.
- NMN combined with L. fermentum is used to display the related factors in the AMPK signaling pathway and the level changes of the related factors through this signal.
- the experimental method was as follows: liver and skin tissues were homogenized and total RNA was extracted with Trizol reagent, and then the RNA was reverse transcribed into cDNA using a cDNA kit. Next, 1 ⁇ L of cDNA, 10 ⁇ L of TaqMan TM Multiplex Master Mix, 2 ⁇ L of 10 ⁇ M primer and 7 ⁇ L of ddH 2 O were mixed evenly, and amplification detection was performed on a real-time fluorescence quantitative PCR instrument.
- the amplification conditions were: deformation at 95°C for 15s, annealing at 55°C for 30s, and extension at 72°C for 35s, for a total of 40 cycles. Finally, the relative expression of each target gene was calculated by 2 - ⁇ CT , in which ⁇ -actin was used as an internal reference gene.
- the primer sequences used are shown in Table 3.
- Figure 4 shows the mRNA expression of AMPK, NF- ⁇ B p65, I ⁇ B- ⁇ , SOD1 and CAT in skin and liver tissues.
- UVB irradiation increased the mRNA expression levels of NF- ⁇ Bp65 in the skin and liver of mice, and decreased the expressions of I ⁇ B- ⁇ , AMPK, SOD and CAT, among which the model group had the most obvious changes. .
- the mRNA expressions of I ⁇ B- ⁇ , AMPK, SOD and CAT in the skin and liver of the VC group and the NMN+L group were increased to varying degrees, while the expression of NF- ⁇ Bp65 was decreased, among which NMN+
- the mRNA expression levels of the above indicators in the L group were close to those in the normal group.
- AMPK mRNA and protein in the liver and skin of mice in the model group was significantly lower than that in the normal group, indicating that UVB irradiation caused energy metabolism disorders in mice, and increased oxidative stress and inflammatory responses.
- NMN combined with L. fermentum gavage treatment can significantly increase the mRNA expression of AMPK in liver and skin tissues, indicating that NMN combined with L. fermentum can effectively promote cellular energy synthesis and reduce the damage caused by oxidative stress and inflammatory reactions.
- Figure 5 shows the mRNA expression levels of PGC-1 ⁇ , APPL1, mTOR, FOXO1, TNF- ⁇ , IL-6, IL-10 and GSH in skin and liver tissues.
- the mRNA expressions of PGC-1 ⁇ , APPL1, FOXO1, IL-10 and GSH in the skin and liver of the normal group mice were the highest, and the expressions of mTOR, TNF- ⁇ and IL-6 were the lowest, while the model Compared with the normal group, the expression levels of the above indexes in the skin and liver of the mice in the group showed a completely opposite trend, and there were significant differences between the two.
- VC and NMN combined with L.
- UVB irradiation can reduce the mRNA expression of APPL1, FOXO1 and PGC-1 ⁇ and increase the mRNA expression of mTOR in mouse skin and liver.
- the mRNA expressions of APPL1, LKB1, SIRT1, FOXO1 and PGC-1 ⁇ in the skin and liver of mice were significantly increased, while the mRNA expression level of mTOR decreased, indicating that NMN combined with L. fermentum can effectively By activating the AMPK signaling pathway, it can improve UVB-induced oxidative stress and inflammation in mice.
- NMN combined with L. fermentum has a relatively obvious improvement effect on UVB-induced skin damage in mice.
- the possible mechanism may be combined with NMN and L. fermentum by activating the AMPK signaling pathway, thereby inhibiting the activation of the NF- ⁇ B signaling pathway, and reducing the damage of inflammatory mediators to mice.
- activated AMPK can reduce the oxidative damage of the skin and improve the overall antioxidant capacity of the body by regulating the levels of related oxidative stress indicators in the serum, liver and skin of mice.
- This study has important reference significance for the prevention and treatment of UVB-induced skin damage, and provides a theoretical basis and available strain sources for the development of NMN combined with Lactobacillus fermentum health food.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/120924 WO2022077276A1 (fr) | 2020-10-14 | 2020-10-14 | Application d'une combinaison de nicotinamide mononucléotide et de lactobacillus fermentum dans la préparation d'une formulation pour soulager le photovieillissement de la peau |
CN202080106065.8A CN117377480A (zh) | 2020-10-14 | 2020-10-14 | 烟酰胺单核苷酸与发酵乳杆菌联合在制备缓解皮肤光老化制剂中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2020/120924 WO2022077276A1 (fr) | 2020-10-14 | 2020-10-14 | Application d'une combinaison de nicotinamide mononucléotide et de lactobacillus fermentum dans la préparation d'une formulation pour soulager le photovieillissement de la peau |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022077276A1 true WO2022077276A1 (fr) | 2022-04-21 |
Family
ID=81207547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/120924 WO2022077276A1 (fr) | 2020-10-14 | 2020-10-14 | Application d'une combinaison de nicotinamide mononucléotide et de lactobacillus fermentum dans la préparation d'une formulation pour soulager le photovieillissement de la peau |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN117377480A (fr) |
WO (1) | WO2022077276A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960742A (zh) * | 2022-07-12 | 2023-04-14 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 具有延长真皮成纤维细胞寿命、抗皮肤老化功能的发酵乳杆菌xjc48及其应用 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186114A1 (fr) * | 2014-06-06 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Analogues de nicotinamide riboside, compositions pharmaceutiques et leurs utilisations |
CN108430482A (zh) * | 2015-11-10 | 2018-08-21 | 伊丽莎白·麦克纳 | 细胞氧化还原水平的控制 |
CN110507672A (zh) * | 2019-08-28 | 2019-11-29 | 杜斌 | 一种高效微生态调整剂及其应用 |
CN111035012A (zh) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | 一种抗氧化营养组合胶囊及其制备方法 |
CN111246838A (zh) * | 2017-10-06 | 2020-06-05 | 艾克斯奥巴德蒙公司 | 用于将活性成分递送至皮肤的套件 |
WO2020150329A1 (fr) * | 2019-01-15 | 2020-07-23 | Microbiome Labs, Llc | Composition probiotique à base de spores pour la modulation de propriétés dermiques et sous-dermiques |
CN111511379A (zh) * | 2017-12-06 | 2020-08-07 | Lac2生物群系有限公司 | 基于益生菌的组合物及其应用 |
-
2020
- 2020-10-14 WO PCT/CN2020/120924 patent/WO2022077276A1/fr active Application Filing
- 2020-10-14 CN CN202080106065.8A patent/CN117377480A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015186114A1 (fr) * | 2014-06-06 | 2015-12-10 | Glaxosmithkline Intellectual Property (No.2) Limited | Analogues de nicotinamide riboside, compositions pharmaceutiques et leurs utilisations |
CN108430482A (zh) * | 2015-11-10 | 2018-08-21 | 伊丽莎白·麦克纳 | 细胞氧化还原水平的控制 |
CN111246838A (zh) * | 2017-10-06 | 2020-06-05 | 艾克斯奥巴德蒙公司 | 用于将活性成分递送至皮肤的套件 |
CN111511379A (zh) * | 2017-12-06 | 2020-08-07 | Lac2生物群系有限公司 | 基于益生菌的组合物及其应用 |
WO2020150329A1 (fr) * | 2019-01-15 | 2020-07-23 | Microbiome Labs, Llc | Composition probiotique à base de spores pour la modulation de propriétés dermiques et sous-dermiques |
CN110507672A (zh) * | 2019-08-28 | 2019-11-29 | 杜斌 | 一种高效微生态调整剂及其应用 |
CN111035012A (zh) * | 2019-12-16 | 2020-04-21 | 青岛赛珥生物医学科技有限公司 | 一种抗氧化营养组合胶囊及其制备方法 |
Non-Patent Citations (1)
Title |
---|
ZHAO CAN, WENJING LI, HAOYUN DUAN, ZONGYI LI, YANNI JIA, SONGMEI ZHANG, XIN WANG, QINGJUN ZHOU, WEIYUN SHI: "NAD+ precursors protect corneal endothelial cells from UVB-induced apoptosis", AM J PHYSIOL CELL PHYSIOL, vol. 318, 12 February 2020 (2020-02-12), pages C796 - C805, XP055922680, DOI: 10.1152/ajpcell.00445.2019 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115960742A (zh) * | 2022-07-12 | 2023-04-14 | 广东省科学院微生物研究所(广东省微生物分析检测中心) | 具有延长真皮成纤维细胞寿命、抗皮肤老化功能的发酵乳杆菌xjc48及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN117377480A (zh) | 2024-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2022001784A1 (fr) | Application d'un inhibiteur de glutaminase dans la préparation d'un médicament pour traiter le psoriasis | |
CN109125107B (zh) | 一种有效改善和修复面部激素依赖性皮炎的多肽组合物 | |
CN106539092A (zh) | 一种绿藻多糖化纳米硒及其制备方法与应用 | |
WO2023005265A1 (fr) | Application d'un mélange de nucléotides dans la préparation de formulations pour la prévention ou le soulagement de la sarcopénie sénile | |
Liu et al. | Molecular mechanisms of anti-cancer bioactivities of seaweed polysaccharides | |
Wu et al. | Chlorella sp.-ameliorated undesirable microenvironment promotes diabetic wound healing | |
Zhou et al. | Nicotinamide mononucleotide combined with lactobacillus fermentum TKSN041 reduces the photoaging damage in murine skin by activating AMPK signaling pathway | |
US20150140112A1 (en) | Composition comprising extract of mixture of undaria pinnatifida sporophylls and ascidian shells for treating atopic dermatitis | |
WO2022077276A1 (fr) | Application d'une combinaison de nicotinamide mononucléotide et de lactobacillus fermentum dans la préparation d'une formulation pour soulager le photovieillissement de la peau | |
WO2018175334A1 (fr) | Compositions et méthodes de traitement d'affections cutanées | |
CN111870609A (zh) | 一种肠道菌群调节剂及其应用 | |
CN102008083B (zh) | 一种缓解体力疲劳、祛黄褐斑的保健食品 | |
CN103897010B (zh) | 一种用于治疗银屑病的组合物及制备方法 | |
WO2022047779A1 (fr) | Utilisation de nicotinamide mononucléotide dans la préparation d'un réactif permettant d'améliorer le niveau d'enzyme na+-k+-atp dans un sarcolemme de peau lésée | |
KR20100059305A (ko) | 저실자 추출물 함유 피부외용제 조성물 | |
Onogawa et al. | Animal studies supporting the inhibition of mast cell activation by Eriobotrya japonica seed extract | |
Lan et al. | Vitamin e succinate inhibits the growth of human gastric cancer cells | |
Murray | Pyrroloquinoline quinone (PQQ): The next essential nutrient and supplement superstar | |
CN114831312B (zh) | 一种由灵芝多糖和金蝉花多糖构成的中药组合物及应用 | |
WO2023155865A1 (fr) | Utilisation d'oligosaccharides de morinda officinalis et composition de ceux-ci dans la prévention ou le traitement de la dépression | |
Buranasudja et al. | DNA Damage and Energy Crisis are Central in the Mechanism for the Cytotoxicity of Pharmacological Ascorbate in Cancer Treatment | |
CN112972391B (zh) | 一种胆红素-jph203纳米颗粒及其制备和应用 | |
WO2022073437A1 (fr) | Utilisation de cannabidiol et sa combinaison avec un extrait de nid d'oiseau comestible dans l'hydratation et l'humidification de la peau | |
Cavalchini et al. | Complementary treatment of psoriasis with an AFA-phyocyanins product: a preliminary 10-cases study | |
CN105287777B (zh) | 一种利尿的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20957057 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202080106065.8 Country of ref document: CN |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20957057 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 20.09.2023) |